annual survey say cro outlook encourag
result survey show acceler spend continu rise outsourc
notabl rise prefer global nich privat player bode
posit growth beyond cogniz recent market
volatil like neg impact biotech fund activ temper
survey enthusiasm also see separ larg
upgrad iqvia buy pt
key driver chang view improv posit cro feedback
survey channel check iqvia done commend job up
sale oper intens busi develop launch integr
applic platform manag project deliveri oper cultur
integr deliv steadi financi perform data survey lead us
increas lt sale growth target move estim consensu
field annual survey target execut profession
larg pharma small biotech question probe intent around
spend major phase outsourc suppli chain strategi decis
influenc survey result follow interview illumin decis process drug
develop outsourc inform lt industri model stock pick
year respons show acceler spend growth across earli
late-stag develop core cro phase perhap correl current
strength pipelin importantli respond indic declin activ pipelin
first time survey
outsourc healthier year
respond also expect increas outsourc penetr glide path would
add underli spend growth rate import expect
peak outsourc penetr jump year particularli late-stag recov
period dour expect
share gain top cro look acceler
cro book growth drop yoy survey
saw satisfact level dip sponsor begin re-expand suppli chain use
yr period narrow partnership strike survey
respons point toward acceler market share gain global larg
small client ad vendor increasingli favor top
rise recognit data strategi lh covanc stand
speed market overwhelm influenc ask respond among
categori achiev driver speed data feasibl earli studi
acceler come top interestingli though patient recruit declin
separ question overtaken mundan global reach
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
summari chang
pleas see import disclosur inform page report
cover pharma servic stock post mix perform rel
 sinc octob introduct volatil biggest smallest
 manag outperform rest under-perform
contract manufactur cbm fell tall bed annual survey
collect insight biopharma execut develop oper outsourc
profession primarili focus cro activ includ topic german
inform technolog data applic drug manufactur develop
report look factor influenc cro activ survey comprehens
effort determin quantit measur growth qualit behavior
driver decis analyz respons total client size larg vs smid
major phase earli develop vs late-stag refer categori
report analys potenti volatil impact biotech fund
impact rfp flow real-tim factor incorpor growth calcul even
believ survey result posit recent year
larger growth acceler anticip prior year
survey respond see growth acceler pretti typic last
survey produc growth outcom interestingli larg pharma respond see
growth smid group forecast slight declin growth rate seemingli
reflect fund concern interestingli larg smid sponsor
expect earli develop grow faster late-stag develop spend
pipelin alloc answer seem support
respond expect outsourc penetr increas unusu yet
two factor stand us first magnitud expect penetr increas
higher survey last two year approach
outsourc enthusiasm express survey chart
data favor earli develop second peak outsourc expect return
optimist level respons return ascend line reflect
pullback expect quantifi term outsourc runway
headroom penetr ceil runway doubl late-stag grew
early-dev improv pronounc larg sponsor posit
lh iclr
global cro continu gain share
year survey shown sponsor prefer engag similar rel
size larg pharma broad pipelin need therefor use larg small
biotech repeat busi command senior execut attent
desir larg use small/nich instead highlight
year-ago survey report align show sign chang survey show
pronounc chang favor larg larg pharma respond award
work mostli larg none work small interestingli smid
sponsor use larg increas percent smid sponsor
use small declin last three year year
life scienc strategi group
survey show pronounc
outsourc prefer
larg
pharma respond stick
interestingli smid sponsor
typic chosen nich shift
materi toward larg well
pleas see import disclosur inform page report
mix bag indic data strategi
take cue combin analysi survey respons follow interview
discuss clinic op leader familiar data strategi
specif seem rise think evid season repetit market
messag familiar respond commend iqvia covanc strategi
often howev ask factor drive cro select overal data fall
decidedli lower half factor discuss privat player reveal strong
growth stabl win rate among small invest data analyt
would pale comparison covanc global player time
hear anecdot small must check box data less clear
close custom scrutin sophist differ strategi
refer back low rank data decis factor short mix bag
chart sponsor choos global cro lower
chart patient recruit like speed
life scienc strategi group jefferi
drug develop world speed speed qualiti job follow cost
patient recruit bottleneck find patient will particip requir
ever-broad geograph reach result growth asia/pac rest world market
steal global share spend dollar us europ remain rel flat
overal though think eastern europ grow expens
largest asia/pac presenc far among publicli trade player
chart sponsor continu move
pleas see import disclosur inform page report
iqvia gain traction safer busi mix midst
upgrad iqvia buy rais pt see four factor drive higher
confid outlook
improv feedback survey channel check cro busi includ
underappreci traction app solut segment particularli
orchestr custom engag oce biosponsor sale market
orchestr clinic trial oct would similar long-term driver clinic
solid overal cro industri outlook slight shift custom import back
toward mid/larg pharma least short medium term iqvia say start
get next gen traction
ep estim consensu front cover
system show cut chang last publish model pick
correctli actual rais
potenti valuat re-rat sum-of-the-part sotp oce traction becom
materi primari comp trade ev/sal vs
mdso comp oct trade ev/sal
cro channel check survey feedback turn posit
combin market pullback need defens
improv custom feedback import chang view despit
lot dig direct convers pharma biotech
provid confirm strong next gen cro uptak import
capabl iqv strategi heighten level investor expect need
compel evid
evid come three sourc survey result report follow interview
clinic oper profession custom non-custom industri
elsewher report survey data show sever posit indic
data identifi promis opportun speed drug develop
covanc identifi top strategi speed patient
recruit score particularli high among smid sponsor consist
high emerg biotech represent next gen book
rank highli second behind covanc attribut import
custom choos larg attribut includ global reach qualiti
work broad servic capabl therapeut expertis
second follow interview anecdot sponsor shed posit light
pleas see import disclosur inform page report
